Pre-order Enquiry
Request Free Sample
COVID-19 Outbreak-Global Opioid-Induced Constipation (OIC) Treatment Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
SKU ID : Maia-15686946 | Publishing Date : 21-May-2020 | No. of pages : 103
Opioids are a class of medications that are regularly endorsed for their pain relieving, or pain-killing, properties it is chronic and non-cancer pain. A typical symptom connected with the utilization of these medications are that they decrease the gastrointestinal tract's motility, making solid discharges and making patients strain. In addition, prolonged utilization of opioids can prompt the harm of sensory system that causes body cells to quit creating endogenous opioids, for example, endorphins. There is high risk of constipation in adults since they have poor diet, poor fluid intake and immobility. The typical symptoms for opioid-induced constipation are feeling lethargic, hard and dry stools, distention and bulged abdomen, painful defecation and loss of appetite. The opioid-induced constipation (OIC) treatment market is an exceptionally alluring and promising market because of the expanding base of opioid-induced constipation OIC sufferers.
The Opioid-Induced Constipation (OIC) Treatment market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Opioid-Induced Constipation (OIC) Treatment industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Opioid-Induced Constipation (OIC) Treatment market can be split based on product types, major applications, and important countries as follows:
Key players in the global Opioid-Induced Constipation (OIC) Treatment market covered in Chapter 12:
Takeda Pharmaceutical Company Limited
S.L.A. Pharma AG
AIKO Biotechnology
AstraZeneca plc, Inc.
Cubist Pharmaceuticals
GlaxoSmithKline, Inc.
Salix Pharmaceuticals, Inc.
Pfizer, Inc.
In Chapter 4 and 14.1, on the basis of types, the Opioid-Induced Constipation (OIC) Treatment market from 2015 to 2025 is primarily split into:
Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA)
Non-selective opioid antagonist
μ-Opioid antagonist
Locally Acting Chloride Channel Activator (LACCA)
In Chapter 5 and 14.2, on the basis of applications, the Opioid-Induced Constipation (OIC) Treatment market from 2015 to 2025 covers:
Drug store
Independent Pharmacies
Hospital Pharmacies
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others
2019
The Opioid-Induced Constipation (OIC) Treatment market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Opioid-Induced Constipation (OIC) Treatment industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Opioid-Induced Constipation (OIC) Treatment market can be split based on product types, major applications, and important countries as follows:
Key players in the global Opioid-Induced Constipation (OIC) Treatment market covered in Chapter 12:
Takeda Pharmaceutical Company Limited
S.L.A. Pharma AG
AIKO Biotechnology
AstraZeneca plc, Inc.
Cubist Pharmaceuticals
GlaxoSmithKline, Inc.
Salix Pharmaceuticals, Inc.
Pfizer, Inc.
In Chapter 4 and 14.1, on the basis of types, the Opioid-Induced Constipation (OIC) Treatment market from 2015 to 2025 is primarily split into:
Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA)
Non-selective opioid antagonist
μ-Opioid antagonist
Locally Acting Chloride Channel Activator (LACCA)
In Chapter 5 and 14.2, on the basis of applications, the Opioid-Induced Constipation (OIC) Treatment market from 2015 to 2025 covers:
Drug store
Independent Pharmacies
Hospital Pharmacies
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years:
2015-2019Base Year:
2019Estimated Year:
2020Forecast Period:
2020-2025Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
